Pregnant and Living with Sickle Cell Disease: A Push for Better Outcomes
NIH, September 2023
From the website: " Experts say that medical advances in care and disease-modifying therapies have helped many people living with SCD survive well through their reproductive years. For parents-to-be, that means awareness is key. Individuals with SCD are at higher risk than the general population for preeclampsia, as Found discovered; but those with preeclampsia can go on to develop a condition called eclampsia, which can lead to seizures and even coma. People with SCD are also at higher risk for sepsis and blood clots. And there are risks for the fetus, such as lower-than-normal growth in the womb, preterm delivery, and stillbirth."
Comparison of pathogen detection consistency between metagenomic next-generation sequencing and blood culture in patients with suspected bloodstream infection.
Yuhua Zhou et al. Sci Rep 2023 6 (1) 9460
The application of metagenomic next-generation sequencing (mNGS) has gradually been carried out by clinical practitioner. However, few studies have compared it with blood cultures in patients suffering from suspected bloodstream infections. The purpose of this study was to compare the detection of pathogenic microorganisms by these two assays in patients with suspected bloodstream infection. We retrospectively studied patients with fever, chills, antibiotic use for more than 3 days, suspected bloodstream infection, and admission to the emergency department of Ruijin Hospital from January 2020 to June 2022.
Why is COVID life-threatening for some people? Genetics study offers clues Immune genes could play a part in the risk of needing intensive care when infected with SARS-CoV-2.
H Ledford, Nature, May 17, 2023
An analysis of DNA from more than 24,000 people who had COVID-19 and required treatment in intensive care has yielded more than a dozen new genetic links to the risk of developing extreme illness from the disease. The study has more than 2,000 authors, highlights the role of the immune system in fuelling the later stages of particularly severe COVID-19. The results could one day contribute to the development of therapies for COVID-19 — and potentially other diseases that cause acute respiratory distress or sepsis.
Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A mendelian randomisation study.
Fergus W Hamilton et al. PLoS medicine 2023 1 (1) e1004174
In a large, UK cohort (N = 485,825, including 11,643 with sepsis), genetic variation acting as a proxy (or natural experiment) for IL6R blockade was associated with a reduced odds of sepsis (odds ratio (OR) 0.80; 95% confidence interval (CI) 0.66 to 0.96) in MR analyses. Effects were consistent in secondary cohorts and when using differing definitions of sepsis, with effect sizes generally larger in more severe phenotypes.